Plaque Psoriasis

More than 80% of patients receiving Tremfya demonstrated PASI 90 scores at week 100.

The long-term study shows biosimilar adalimumab, if approved, will further improve access to treatment for immunological diseases.

The drug is the first and only fully-human antagonist showing sustained skin clearance rates at 5 years.

The drug is being marketed as the cheapest injectable psoriasis treatment available in the US.

The FDA has approved guselkumab for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The FDA has approved brodalumab for moderate-to-severe plaque psoriasis in patients who are eligible for systemic therapy or phototherapy and who have failed to respond or stopped responding to other systemic therapies.

Nearly one-third of patients with plaque psoriasis will also be diagnosed with psoriatic arthritis. While somewhat common, this diagnosis requires a different approach to care in order to help patients better manage their symptoms.

With plaque psoriasis becoming an increasingly common condition providers are able to more easily identify the condition than they had in the past. Looking for red scaling plaques, and thickened skin, as well as asking questions can get doctors the answers they need. In rare cases skin biopsies are also performed.

The days of patients with plaque psoriasis being treated with tar and special lights are fading as new agents, especially oral agents, are being developed.

For many patients, chronic idiopathic urticaria can be a debilitating condition affecting them at all hours of the day and making living with the condition very difficult. Because of this, the need for newer, more effective treatments is driving the field forward at a rapid pace.

Patients with active psoriatic arthritis treated with secukinumab for 2 years in the FUTURE-1 trial experienced sustained decreases in disease activity and symptoms, leading to improvements in physical function and quality of life.

A new model that combines real-world prices with outcome data from both controlled trials and clinical practice indicates that the immediate use of tumor necrosis factor inhibitors (anti-TNFs) is a cost-effective way to achieve good first-year outcomes in patients newly diagnosed with both plaque psoriasis and psoriatic arthritis.

The process for treatment of plaque psoriasis can be a very involved process depending on their history with the condition and other issues they may have as well. This can include psoriatic arthritis.

As newer treatment options hit the market for plaque psoriasis patients may have more questions about the best options for them. This is part of the importance of communicating with patients throughout the treatment process.

For patients diagnosed with plaque psoriasis there can be other health issues to consider as well. This can include heart attack, stroke, and obesity as well as obesity and others.

As with many conditions, the kind of care a patient receives can depend on where they live. This can be especially true for dermatology patients needing things like phototherapy. Other factors, like cost and fear, can also impede the treatment process.

Despite the life of a patient with eczema being in many ways similar to that of a patient with psoriasis, their options for treatment are not nearly as robust as the other dermatologic condition.

As patients go through the process of treating their plaque psoriasis, there can be different levels of success depending on a number of situations. As a result, measuring success can be a challenge as well.

With most cases of plaque psoriasis being diagnosed in adolescence the treatment and diagnosis can be a delicate process, especially when parents are involved.

As new treatments for plaque psoriasis are developed the field as a whole is taking a new look at the condition. However, there are still challenges to overcome in diagnosis and treatment.

It was not long ago that patients diagnosed with plaque psoriasis would require a month-long hospital stay for a short-lived treatment of the condition.

Many psoriasis patients wish they were better informed of the significant impact their skin condition would have on their physical and mental health, according to results from Psoriasis in America 2016, a Health Union national survey.

The US Food and Drug Administration's (FDA's) Arthritis Advisory Committee recently voted unanimously to recommend the approval of biosimilars to adalimumab (Humira) and etanercept (Enbrel).

A new study found that female psoriasis patients have a fourfold increased risk of developing Crohn’s disease (CD).

A family history of heart attacks increases psoriasis patients’ odds of having heart attacks and strokes.

Novartis conducted a global survey of 8,338 patients with moderate-to-severe psoriasis across 31 countries to assess patients’ perceptions of what constitutes “clear skin.â€

While psoriasis has long been linked to other inflammatory conditions, there is little information about psoriasis-related hospitalization.

In patients diagnosed with psoriasis, disease severity has been strongly associated with developing a higher risk of comorbidities affecting the kidney, liver, and pancreas.

Patients suffering from psoriasis are at increased risk of developing serious infections.

It is frustrating, to say the least, when your patients take their frustrations out on you. And, as if having to deal with an angry patient isn’t bad enough, providers now have to worry about the threat of legal action more than ever before.